Literature DB >> 7559902

Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas.

J Zedenius1, C Larsson, U Bergholm, J Bovée, A Svensson, B Hallengren, L Grimelius, M Bäckdahl, G Weber, G Wallin.   

Abstract

The hereditary multiple endocrine neoplasia syndromes types 2A and B (MEN 2A and B) were recently linked to germline mutations in the RET proto-oncogene, altering one of five cysteine residues in exon 10 or 11 (MEN 2A), or substituting a methionine for a threonine at codon 918 in exon 16 (MEN 2B). The latter mutation also occurs somatically in some sporadic medullary thyroid carcinomas (MTC), and has in a previous study been correlated with a less favorable clinical outcome. In the present study, 46 MTCs were selected for investigation of the codon 918 mutation. The mutation was found in 29 tumors (63%), and was significantly correlated with a poor outcome, with regard to distant metastasis or tumor recurrence (p < 10(-4)). Two tumors showed multifocal growth and C-cell hyperplasia, and these patients were therefore also investigated for germline mutations in exons 10, 11 and 16. The codon 918 mutation was found only in the tumors, thus of somatic origin. The RET codon 918 mutation may have prognostic impact, and therefore preoperative assessment may influence decision-making in the treatment of patients suffering from MTC.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7559902     DOI: 10.1210/jcem.80.10.7559902

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  28 in total

Review 1.  Multiple endocrine neoplasia type 2 and the practice of molecular medicine.

Authors:  C Eng
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

2.  Does a somatic deletion in RET clarify the sporadic nature of medullary thyroid carcinoma?

Authors:  O Gimm; D J Marsh
Journal:  J Endocrinol Invest       Date:  2003-04       Impact factor: 4.256

3.  Prognostic significance of disseminated tumor cells in the connective tissue of patients with medullary thyroid carcinoma.

Authors:  Oliver Gimm; Viola Heyn; Ulf Krause; Carsten Sekulla; Jörg Ukkat; Henning Dralle
Journal:  World J Surg       Date:  2006-05       Impact factor: 3.352

4.  Medullary thyroid cancer, papillary thyroid microcarcinoma and Graves' disease: an unusual clinical coexistence.

Authors:  G Mazziotti; M Rotondi; G Manganella; R Franco; V Colantuoni; G Amato; C Carella
Journal:  J Endocrinol Invest       Date:  2001-12       Impact factor: 4.256

Review 5.  Molecular genetics of thyroid cancer.

Authors:  Maha Rebaї; Ahmed Rebaї
Journal:  Genet Res (Camb)       Date:  2016-05-13       Impact factor: 1.588

6.  Searching for non-RET molecular alterations in medullary thyroid carcinoma: expression analysis by mRNA differential display.

Authors:  Thomas J Musholt; Julia Hanack; Christoph Brehm; Reinhard von Wasielewski; Petra B Musholt
Journal:  World J Surg       Date:  2005-04       Impact factor: 3.352

Review 7.  Multiple endocrine neoplasia type 2.

Authors:  Mariola Peczkowska; Andrzej Januszewicz
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

8.  Genetic alterations in quadruple malignancies of a patient with multiple sclerosis: their role in malignancy development and response to therapy.

Authors:  Zorica Milosevic; Nikola Tanic; Jasna Bankovic; Tijana Stankovic; Marko Buta; Dragana Lavrnic; Zorka Milovanovic; Gordana Pupic; Sonja Stojkovic; Vedrana Milinkovic; Yasuhiro Ito; Radan Dzodic
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

Review 9.  Sporadic and familial medullary thyroid carcinoma: state of the art.

Authors:  Tricia A Moo-Young; Amber L Traugott; Jeffrey F Moley
Journal:  Surg Clin North Am       Date:  2009-10       Impact factor: 2.741

10.  Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma.

Authors:  E Chiefari; D Russo; D Giuffrida; G A Zampa; D Meringolo; F Arturi; I Chiodini; D Bianchi; M Attard; V Trischitta; R Bruno; P Giannasio; A Pontecorvi; S Filetti
Journal:  J Endocrinol Invest       Date:  1998-06       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.